Cardiotrophin and uses therefor
AssigneeGenentech, Inc.
InventorsJoffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
Life of this patent
Estimating the term…
Abstract
Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. CT-1 is shown to bind to and activate the receptor, LIFRβ. These CT-1 molecules are shown to influence hypertrophic activity, neurological activity, and other activities associated with receptor LIFRβ. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, neurological disorders, and other disorders associated with the LIFRβ.
Claims25
A method of enhancing the maintenance of pregnancy in a mammal into which an embryo has been introduced, the method comprising prior to said introducing, culturing at least one embryo in a medium containing an amount of CT-1 for sufficient time and under appropriate conditions so as to effect an enhancement of the maintenance of pregnancy in said mammal.
A composition, comprising pluripotential embryonic stem cells and CT-1, a fibroblast growth factor, membrane associated steel factor, and soluble steel factor, the factors present in amounts to enhance the growth of and allow the continued proliferation of the cells.
A composition, comprising primordial germ cells and CT-1, a fibroblast growth factor, membrane associated steel factor and soluble steel factor, the factors present in amounts to enhance the growth of and allow the continued proliferation of the cells.
A composition, comprising embryonic ectoderm cells and CT-1, fibroblast growth factor, membrane associated steel factor and soluble steel factor, the factors present in amounts to enhance the growth of and allow the continued proliferation of the cells.
A composition, comprising CT-1, fibroblast growth factor, membrane associated steel factor, and soluble steel factor in amounts to enhance the growth of and allow the continued proliferation of primordial germ cells.
A composition, comprising CT-1, a fibroblast growth factor, membrane associated steel factor, and soluble steel factor in amounts to promote the formation of pluripotent embryonic stem cells from primordial germ cells.
A method of making a mammalian pluripotential embryonic stem cell, comprising administering a growth enhancing amount of CT-1, a basic fibroblast growth factor, membrane associated steel factor, and soluble steel factor to primordial germ cells under cell growth conditions, thereby making a pluripotential embryonic stem cell.
A method of making a pluripotential embryonic stem cell comprising administering a growth enhancing amount of CT-1, a basic fibroblast growth factor, membrane associated steel factor, and soluble steel factor to embryonic ectoderm cells under cell growth conditions, thereby making a pluripotential embryonic stem cell.
A method of stimulating the proliferation and differentiation of mammalian satellite cells into myoblasts, which method comprises contacting said cells with a stimulation-effective amount of CT-1 for a time and under conditions sufficient for said satellite cells to proliferate and differentiate into myoblasts.
A method of myoblast transfer, comprising contacting mammalian satellite cells with a proliferation- and differentiation-effective amount of CT-1 for a time and under conditions sufficient for said satellite cells to proliferate and differentiate into myoblasts and then administering said myoblasts at multiple sites into muscles.
A method of treating a neoplatic disorder, comprising administering to a population of cells that-comprise neoplastic cells of a patient in need of such treatment a therapeutically effective amount of CT-1.
The method of claim 16, wherein the neoplastic disorder is selected from the group consisting of a carcinoma, sarcoma, melanoma, lymphoma, and leukemia.
A method of treating a mammal afflicted with arthritis or an inflammatory disease, comprising administering to the mammal in need of such treatment an amount of CT-1 antagonist which is effective for alleviation of the condition.
A method of treating a neuron other than a ciliary ganglion neuron, comprising providing the neuron with an amount of CT-1 effective to promote neuronal survival, growth, regeneration, or sprouting.
A method of modulating a neuron's phenotype, comprising providing the neuron with an amount of CT-1 effective to promote a change in neuronal phenotype.
Dependencies are inferred from the claim text.